How can we improve peptide drug discovery? Learning from the past

References

• Muttenthaler M, King GF, Adams DJ, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20:309–325.
   PubMed Web of Science ®Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707.
   PubMed Web of Science ®Google Scholar
• Craik DJ, Fairlie DP, Liras S, et al. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81:136–147.
   PubMed Web of Science ®Google Scholar
• Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J. Med Chem. 2018;61(4):1382–1414.
   Web of Science ®Google Scholar
• Philippe GJB, Craik DJ, Henriques ST. Converting peptides into drugs targeting intracellular protein–protein interactions. Drug Discov Today. 2021;26(6):1521–1531.
   PubMed Web of Science ®Google Scholar
• Research report: peptide therapeutics market, 2021–2030, roots analysis. 2021. p. 1–333.
   Google Scholar
• de la Torre BG, Albericio F. Peptide therapeutics 2.0. Molecules 2020;25(10):2293.
   Web of Science ®Google Scholar
• Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277–289.
   PubMed Web of Science ®Google Scholar
• Zompra AA, Galanis AS, Werbitzky O, et al. Manufacturing peptides as active pharmaceutical ingredients. Future Med Chem. 2009;1(2):361–377.
   PubMed Web of Science ®Google Scholar
• Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem. 2019;84(8):4615–4628.
   PubMed Web of Science ®Google Scholar
• D’Aloisio V, Dognini P, Hutcheon GA, et al. PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics. Drug Discov Today. 2021;26(6):1409–1419.
   PubMed Web of Science ®Google Scholar
• Jing X, Jin K. A gold mine for drug discovery: strategies to develop cyclic peptides into therapies. Med Res Rev. 2020;40(2):753–810.
   PubMed Web of Science ®Google Scholar
• Zorzi A, Deyle K, Heinis C. Cyclic peptide therapeutics: past, present and future. Curr Opin Chem Biol. 2017;38:24–29.
   PubMed Web of Science ®Google Scholar
• Góngora-Benítez M, Tulla-Puche J, Albericio F. Multifaceted roles of disulfide bonds Peptides as therapeutics. Chem Rev. 2014;114:901–926.
   PubMed Web of Science ®Google Scholar
• De Veer SJ, Kan M-W, Craik DJ. Cyclotides: from structure to function. Chem Rev. 2019;119(24):12375–12421.
   PubMed Web of Science ®Google Scholar
• Sawyer TK, Partridge AW, Kaan HYK, et al. Macrocyclic α helical peptide therapeutic modality: a perspective of learnings and challenges. Bioorg Med Chem. 2018;26(10): 2807–2815.
   PubMed Web of Science ®Google Scholar
• Baeriswyl V, Calzavarini S, Chen S, et al. A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation. ACS Chem Biol. 2015;10(8):1861–1870.
   PubMed Web of Science ®Google Scholar
• Jin A-H, Muttenthaler M, Dutertre S, et al. Conotoxins: chemistry and biology. Chem Rev. 2019;119(21):11510–11549.
   PubMed Web of Science ®Google Scholar
• Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2013;8(2):219–244.
   PubMed Web of Science ®Google Scholar
• Hetrick KJ, van der Donk WA. Ribosomally synthesized and post-translationally modified peptide natural product discovery in the genomic era. Curr Opin Chem Biol. 2017;38:36–44.
   PubMed Web of Science ®Google Scholar
• Getz JA, Cheneval O, Craik DJ, et al. Design of a cyclotide antagonist of neuropilin-1 and −2 that potently inhibits endothelial cell migration. ACS Chem Biol. 2013;8(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wiedmann MM, Suga H. RNA display methods for the discovery of bioactive macrocycles. Chem Rev. 2019;119(17):10360–10391.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.
   PubMed Web of Science ®Google Scholar
• Zhang W, Yu L, Ji T, et al. Tumor microenvironment–responsive peptide-based supramolecular drug delivery system. Front Chem. 2020;8:549.
   PubMed Web of Science ®Google Scholar
• Bhardwaj G, Mulligan VK, Bahl CD, et al. Accurate de novo design of hyperstable constrained peptides. Nature 2016;538(7625):329–335.
   PubMed Web of Science ®Google Scholar
• Afb R, Reichart F, Weinmüller M, et al. Improving oral bioavailability of cyclic peptides by N-methylation. Bioorg Med Chem. 2018;26(10):2766–2773.
   PubMed Web of Science ®Google Scholar
• Wang CK, Northfield SE, Colless B, et al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc Natl Acad Sci U S A. 2014;111(49): 17504–17509.
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Hill TA, Fairlie DP, et al. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 2020;157:2–36.
   PubMed Web of Science ®Google Scholar
• deGruyter JN, Malins LR, Baran PS. Residue-specific peptide modification: a chemist’s guide. Biochemistry 2017;56(30):3863–3873.
   PubMed Web of Science ®Google Scholar
• Dougherty PG, Sahni A, Pei D. Understanding cell penetration of cyclic peptides. Chem Rev. 2019;119(17):10241–10287.
   PubMed Web of Science ®Google Scholar
• Lee ACL, Harris JL, Khanna KK, et al. A comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 2019;20:21.
   Web of Science ®Google Scholar
• Basith S, Manavalan B, Hwan Shin T, et al. Machine intelligence in peptide therapeutics: a next-generation tool for rapid disease screening. Med Res Rev. 2020;40:1276–1314.
   Google Scholar
• Chevalier A, Silva D-A, Rocklin GJ, et al. Massively parallel de novo protein design for targeted therapeutics. Nature 2017;550(7674):74–79.
   PubMed Web of Science ®Google Scholar
• Yap K, Du J, Rehm FBH, et al. Yeast-based bioproduction of disulfide-rich peptides and their cyclization via asparaginyl endopeptidases. Nat Protoc. 2021;16(3):1740–1760.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Yap K, Poth AG, et al. Rapid and scalable plant-based production of a potent plasmin inhibitor peptide. Front Plant Sci. 2019;10:602.
   PubMed Web of Science ®Google Scholar
• de la Torre BG, Albericio F. The pharmaceutical industry in 2018 An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2019;24(4):809.
   Web of Science ®Google Scholar